Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall reports revenue growth in Q3 2012

Almirall reports revenue growth in Q3 2012

19th November 2012

Almirall has expressed satisfaction with its financial performance in the third quarter of 2012, which was reported to be in line with its prior expectations.

The pharmaceutical company's sales total for the year to date came to 706.7 million euros (567.23 million pounds), up by 5.7 percent year over year, with international business now accounting for nearly 60 percent of its sales.

Newly-launched products such as Eklira and the company's growing dermatology franchise were strong drivers of growth during the quarter, while European approval of linaclotide is expected before the end of the year.

The firm also announced plans to enter the share capital of Spanish biotechnology company and partner AB-Biotics last month, a deal that will allow it to enter the pharmacogenetics and personalised medicine market.

Almirall has reiterated its financial guidance for the full year, as results continue to align with previous forecasts.

Eduardo Sanchiz, chief executive officer of Almirall, said: "Almirall keeps the momentum in 2012, with positive news when it comes to our new products that should be a stepping stone to ensure a sustainable mid and long-term strong growth."ADNFCR-8000103-ID-801490226-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.